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Background: A close match of the HLA alleles between donor and recipient is an important prerequisite for
successful unrelated hematopoietic stem cell transplantation. To increase the chances of finding an unrelated
donor, registries recruit many hundred thousands of volunteers each year. Many registries with limited resources
have had to find a trade-off between cost and resolution and extent of typing for newly recruited donors in the
past. Therefore, we have taken advantage of recent improvements in NGS to develop a workflow for low-cost,
high-resolution HLA typing.
Results: We have established a straightforward three-step workflow for high-throughput HLA typing: Exons 2 and 3
of HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1 are amplified by PCR on Fluidigm Access Array microfluidic chips. Illumina
sequencing adapters and sample specific tags are directly incorporated during PCR. Upon pooling and cleanup,
384 samples are sequenced in a single Illumina MiSeq run. We developed “neXtype” for streamlined data analysis
and HLA allele assignment. The workflow was validated with 1140 samples typed at 6 loci. All neXtype results were
concordant with the Sanger sequences, demonstrating error-free typing of more than 6000 HLA loci. Current
capacity in routine operation is 12,000 samples per week.
Conclusions: The workflow presented proved to be a cost-efficient alternative to Sanger sequencing for
high-throughput HLA typing. Despite the focus on cost efficiency, resolution exceeds the current standards of
Sanger typing for donor registration.
Keywords: Human leukocyte antigen, HLA typing, NGS, Dual indexing, 4-primer approach, Amplicon-based
sequencing, Fluidigm Access Array, Illumina MiSeqBackground
The success of unrelated hematopoietic stem cell trans-
plantation is closely linked to a good match of the HLA
genes between donor and recipient [1]. To overcome the
odds of finding a matching donor – given the high diver-
sity of the HLA system (>8000 described alleles) – many
organizations worldwide endeavor to characterize the
HLA types of volunteers. In 2012 alone, 1.6 million new
potential donors were registered. Typing potential do-
nors upfront for 5 loci at high resolution would be
highly beneficial in speeding up the search process,* Correspondence: boehme@dkms-lab.de
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reproduction in any medium, provided the orthereby saving precious time for patients in need of a
transplantation [2]. However, due to the cost of high
resolution HLA typing based on Sanger sequencing,
many organizations restrict the number of loci typed to
HLA-A,-B and-DRB1 or even restrict the number of po-
tential donors to be recruited. After revolutionizing gen-
ome sequencing, NGS is expected to also markedly
change the diagnostic market. HLA typing by NGS has
been demonstrated by performing long range PCR in
combination with shotgun sequencing [3-5]. However,
the required sophisticated sample preparation steps and
associated costs make that approach currently more at-
tractive for patient samples than for cost-sensitive high-
throughput stem cell donor registry typing. Several
groups have demonstrated the feasibility of HLA typingtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Moonsamy et al. streamlined the workflow considerably
by taking advantage of the Fluidigm Access Array tech-
nology for performing up to 48 × 48 (2048) PCR reac-
tions on a single chip [8]. Given the improvements in
read length to 2 × 250 base pairs, the Illumina MiSeq
system seemed compatible for an amplicon sequencing
approach as well. We have therefore set out to transfer
the strategy of Moonsamy et al. to the MiSeq. In contrast
to the 454 system, the MiSeq features on-board clonal
amplification, thereby greatly simplifying sample prepar-
ation and rendering the workflow more amendable for
high-throughput routine operation. In addition, the oper-
ational cost is greatly reduced, with a more than 50 fold
reduced cost per read compared with the 454 GS FLX sys-
tem. Taken together, those features allowed us to develop
a high-throughput low-cost HLA sequencing workflow
that would render typing of the transplantation-relevant
genes and exons affordable for donor centers.
Results and discussion
Workflow
The workflow (Figure 1) consists of three straightforward
steps starting with DNA isolated from human blood. Since
we did not find a correlation between the number of reads
and pre-PCR DNA concentration (Figure 2), we haveFigure 1 Workflow for analyzing 384 samples. 8 Fluidigm chips with 48omitted DNA normalization for the sake of cost and sim-
plicity. HLA-specific DNA amplification by PCR is per-
formed on Fluidigm Access Array microfluidic chips [8].
These chips feature the combination of 48 samples with
48 primer groups for PCR amplification in 2048 indi-
vidual 35 nl reaction chambers. Before application to the
Fluidigm chip, the 48 samples are mixed with primer sets
containing unique indexing nucleotide sequences and
adapter sequences to allow direct sequencing of the PCR
products on the MiSeq without the need of additional li-
brary preparation steps (Figure 3). We take advantage of
the capabilities of the MiSeq to sequence two indices in
addition to the two paired-end 250 base pair sequencing
reads. Using 8 bases for each index, we employed 96 index
sequences for index1 and 16 index sequences for index2,
resulting in 1536 unique combinations. During each
MiSeq run, we multiplex 384 samples. Therefore, 3 out of
4 index combinations are not used in a particular run,
minimizing index mis-assignments [9]. Following PCR, the
48 samples of one Fluidigm chip are pooled. The pool is
purified using solid phase reversible immobilization (SPRI)
bead technology with a lower DNA size cut-off of 250 base
pairs to remove primer-dimer products. The purified pool
is quantified by qPCR to adjust for slightly different ampli-
fication efficiencies of individual chips. Aliquots of 8 puri-
fied pools corresponding to 384 samples are combined,samples each are pooled for one MiSeq run.
Figure 2 Correlation of DNA concentration and total reads for 384 samples. Mean DNA concentration: 77 ng/μl, mean number of reads:
30,605, coefficient of correlation: 0.26.
Figure 3 Dual indexing in a 4-primer approach. The 2 outer and 2 inner primers are combined in one PCR reaction to yield a MiSeq
compatible product with dual indexing. Each sample is first mixed with a unique combination of outer primer indexes. The 48 samples are then
combined with up to 48 target-specific primer sets in 2304 separate reaction chambers on the Fluidigm chip for PCR.
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10% PhiX onto a MiSeq instrument.
Optimization of primers and PCR conditions
The primer sets are key to a successful short amplicon
HLA typing strategy. We developed primer sets targeting
HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1, restricting
ourselves to exons 2 and 3 for all loci (Figure 4). Exons 2
and 3 (of HLA class I genes; only exon 2 for HLA class II
genes) represent the antigen recognition site and are
therefore regarded as most relevant for unrelated stem cell
transplantation [10-12]. However, limiting the sequenced
region to exon 2 and 3 is a compromise which leaves
unresolved certain allele ambiguities that are outside this
region. Since the medical relevance of such ambiguitiesFigure 4 Location of HLA specific primers. Primers are located in the in
the exonic sequence with the exception of HLA-DQB1 exon 3 forward and
exonic sequence.(with the exception of null alleles) is uncertain, they are
currently not considered for donor selection in the con-
text of unrelated stem cell transplantation. Therefore, in
the context of registry typing, to focus on exon 2 and 3 is
justifiable.
HLA typing poses a particular challenge for primer
selection. Despite the enormous diversity, well-balanced
amplification of both alleles – independent of the allele
combination – needs to be assured. High specificity is
required to distinguish several evolutionary related, highly
homologous genes. Furthermore, to cover the full exons
of around 270 base pairs, the primers may not be too
distant from the exon-intron boundaries. We developed a
rigorous procedure based on the rich content of NGS
data for testing the primer sets for specificity and eventrons surrounding exon 2 or 3 respectively. There is no overlap with
HLA-DRB1 exon 3 reverse which overlap by few bases with the
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HLA type (Figure 5). This allowed us to fine tune the pri-
mer sets for optimal performance:
In contrast to Sanger based sequencing, using NGS
unspecific amplification does not result in noisy sequen-
cing data. Due to the clonal sequencing, the unspecific
amplification products are easily identified by the ana-
lysis software. Nevertheless, specificity is preferred to
maximize the relevant information of the available reads.
Likewise, with regard to unbalanced amplification,
the NGS approach is considerably more sensitive in
detecting suppressed alleles than Sanger sequencing
which requires at least 5% to 20% of the weaker allele
for detection [13]. In contrast, given sufficient read depth,
our analysis software “neXtype” identifies suppressed al-
leles down to 2% read count relative to the dominant al-
lele. In addition, to avoid false homozygous results,
neXtype blocks homozygous calls with less than 100 reads
(20 fold above the detection limit). Despite the increased
sensitivity for suppressed alleles, we went through severalFigure 5 Optimization and performance of primer sets. (a) Classificatio
Q-values. PCR artifacts resulting in artificial hybrids of allele1 and allele2 are
Example of an optimized primer set (A Exon 2) demonstrating balanced am
sets - Allele amplification bias: Example of an unoptimized primer set (B E
and B*27. (d) Crossover artifact quantification: 48 samples were amplified usin
for each locus and exon. Sample-loci with homozygous results were not cons
the crossover-rate.rounds of primer optimization to come up with a set of
primers with well-balanced amplification independent of
the given allele combination (Figure 5 b,c). As part of our
quality control, every new batch of primers is tested
against a set of 95 samples to confirm well-balanced amp-
lification, i.e. no second allele detected with less than 20%
of the reads of the dominant allele. This set of samples
was carefully selected to represent at least 2 samples for
each allele group targeted by a particular primer in the
primer group.
We also monitor the occurrence of artifacts previously
reported in the literature: The generation of artificial
“recombinant” or “chimeric” PCR products from the two
alleles present in a sample. Such “crossover” events have
been described as potential error source of HLA-DRB1
typing, as particular crossover events of HLA-DRB1 and
HLA-DRB3/4/5 are identical to named HLA-DRB1 al-
leles [14-16]. We quantified the rate of crossover products
(Figure 5a). Depending on the targeted exon, an average
of up to 25% of the matched reads were identified asn of reads based on known typing results using sequence and
reported as “crossover“. (b) Optimization of primer sets - Allele balancing:
plification and sufficient read counts. (c) Optimization of primer
xon 3) demonstrating negative amplification bias for allele groups B*14
g 30 to 36 PCR cycles and the rate of crossover formation was quantified
idered for analysis. Lowering the number of PRC cycles reduces
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previous quantitative analyses in the context of HLA, our
findings are nonetheless in accordance with reports in the
context of 16S sequencing [17]. Since most of the cross-
over products are generated during the late PCR cycles,
the artifact may be reduced by decreasing the number of
PCR cycles [18] (Figure 5d). However, in the interest of
maximum robustness with regard to samples with low
DNA concentration, we have chosen not to reduce PCR
cycles below 32 cycles but have rather extended neXtype
to handle the artifacts properly.
HLA allele calling
We developed the NGS HLA typing software “neXtype”
to match the throughput of the workflow. NeXtype takes
full advantage of Q values and high coverage to auto-
mate data analysis as far as possible without compromis-
ing accuracy. Statistical algorithms are implemented to
a) identify new alleles, and b) distinguish between se-
quencing artifacts and closely related alleles. Currently,
more than 95% of the typing assignments do not require
any manual corrections. Taking advantage of the high
number of reads per amplicon and the high quality of
base-calls, we have chosen a set of highly conservative
parameters for “autotyping”: Those typing assignments
(82%) do not even need to be reviewed by a human
analyst. To qualify for this category (among other re-
strictions), homozygous calls are accepted only if the
read count is high enough to safely exclude a potentially
suppressed second allele, taking imbalanced amplifica-
tion of up to 20:1 into account. The 18% of typings not
meeting the autotyping criteria remain for analyst review
and are divided into three categories: 13% require user
confirmation, 2.7% requiring user editing and 2.3% failed
typings. Due to the high level of automation, analysis of
384 samples (2304 loci) can be performed in less than 3
hours by one trained analyst.
Validation
We validated the workflow including neXtype analysis
software by analyzing 1140 samples of known HLA
type. All common alleles with frequency >0.001 in the
German population were represented by at least 2 samples
[19]. Using 24 Fluidigm Access Array chips we amplified
12 HLA targeted exons per sample and sequenced them in
3 MiSeq runs. In the case of 160 sample-loci (2.3%),
data quality was insufficient and these were therefore
excluded from further analysis. All alleles of the 160
sample-loci that failed were successfully typed by this ap-
proach in other samples. Therefore, these failures were
classified as technical failures independent of HLA type.
In routine operation those technical failures need to be re-
peated. Those failures do however not compromise HLA
typing accuracy. Subsequent to analysis using neXtype,the results were compared with the typing results ob-
tained by Sanger sequencing: All NGS neXtype results
were concordant with the Sanger sequences, demonstrat-
ing error-free typing for more than 6000 sample-loci.
Routine operation
Upon successful validation, we started routine operations.
Within 6 weeks of operations, we achieved a throughput
of more than 3500 samples or 21,000 sample-loci per
week. Using Sanger sequencing, more than 800 sequen-
cing runs (96 capillaries) would be required for equal
throughput. Capacity was increased to 12,000 samples per
week within 12 months. The workflow has proven very re-
liable. Analyzing 9 early runs, only 0.6% (22 out of 3420)
of the samples resulted in less than 5000 reads per sample.
Depending on the targeted exon, we consistently obtain
1000 to 3000 fold coverage (median) with only 9 sample-
exons (out of 20,388) below 250 reads (Figure 6).
Comparing the resolution obtained from Sanger-based
registry typing with our NGS workflow demonstrates
that the NGS workflow yields an increased rate of high
resolution typings (Table 1). And this despite the fact
that, an average of five GSSP reactions per sample were
performed and analyzed on the Sanger to resolve phase
ambiguities as far as possible.
Conclusion
Comparing the proposed workflow with conventional
Sanger sequencing, it is apparent that the NGS workflow
is more cost-efficient and easier to set up. In contrast to
Sanger sequencing, the individual sample needs to be
handled only when it is combined with the barcode se-
quence, loaded onto the Access Array chip and pooled
with other samples after PCR. To exclude sample mix
up by design, we have set up 2 liquid handlers with bar-
code reading capabilities. However, the process as such
could easily be handled by manual pipetting. Therefore,
it appears to be an attractive alternative to Sanger se-
quencing even for labs with far lower throughput. Given
the combined chip and sequencing run costs of about
$1000 (list price Access Array chip and MiSeq Reagent
Nano Kit 500 cycles), HLA typing by NGS as proposed
here seems to be more cost-efficient, starting with as
few as 24 samples, even when compared with Sanger se-
quencing costs alone. At the same time, it was possible
to further increase resolution by sequencing more exons
and introns of up to 48 targeted amplicons at no signifi-
cant additional cost. For the purpose of typing for HLA
registries, we have restricted the number of amplicons to
the exons most relevant for the donor search to rou-
tinely multiplex 384 samples. In high throughput oper-
ation, we achieved a cost reduction of more than 50%
compared with cost-optimized Sanger sequencing. These
realized savings lower the cost for high resolution typing
Figure 6 Coverage. Reads per amplicon and sample over 9 runs (3398 samples). Boxes represent median and first and third quartile, whiskers
correspond to the interquartile range and outliers are plotted.
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registered donors with the same budget and simultan-
eously improving typing resolution. Both factors should
facilitate and accelerate the search process and thus im-




All samples used were blood samples, collected in veno-
safe 4 ml EDTA tubes (Terumo, Tokyo, Japan). Validation










Rate of high resolution typing results. Resolution of 37,975 samples typed by
the proposed NGS approach in September 2013 was compared with 145,932
samples analyzed by Sanger sequencing in 2012. In accordance with the
standards of the European Federation for Immunogenetics (EFI), we refer to
allele typing results with no ambiguities in the antigen recognition site as
“high resolution”.DKMS donors in Germany. Ethnic background is self-
assigned at recruitment by country code of origin.
85% of the donors described themselves as German,
7% as Turkish, 1% as polish donors, 5% came from
33 different countries and from 2% no ethnic infor-
mation is reported. Upon registration, donors sign an
informed consent approving HLA typing and storage
of samples for future typings related to stem cell trans-
plantation. No ethics committee approval was obtained as
sequencing-based HLA typing of potential stem cell do-
nors is standard practice for stem cell donor centers and
is covered by the donor consent form signed at recruit-
ment. DKMS Life Science Lab is an affiliated company
with DKMS German Bone Marrow Donor Center and
performs HLA typing on request of DKMS.
Sanger sequencing
All samples have been typed for HLA-A, -B, -C, -DRB1,
-DQB1, and -DPB1 by Sanger sequencing using inhouse
primers on a 3730xl capillary sequencer (Life Technologies,
Carlsbad, USA) at the time of donor registration. These
typings have been used for validation. The Sanger sequen-
cing strategy involved amplification spanning exons 2 and 3
for HLA-A, -B, -C; two separate amplicons for exons 2 and
3 for HLA-DQB1 and -DPB1 and one amplicon for Exon 2
for HLA-DRB1. All primers were located in the introns. Se-
quencing was carried out separately for all exons, and
group specific sequencing primers (GSSP) were used to re-
solve ambiguities.
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DNA was isolated from 150 μl whole blood (EDTA)
based on magnetic bead technology with “chemagic
DNA Blood kit 150 special” (PerkinElmer, Baesweiler,
Germany) using “chemagic Magnetic Separation Module
I” (PerkinElmer, Baesweiler, Germany). DNA was eluted
in 100 μl elution buffer (10 mM Tris–HCl pH8.0) yield-
ing concentrations of between 35 and 100 ng/μl as de-
termined by UV on NanoQuant plate using TECAN
infinite 200Pro (Tecan, Männedorf, Switzerland) plate
reader.
PCR amplification with the access array system
PCR amplification was performed using a 48.48 Fluidigm
Access Array (Fluidigm Corporation, South San Francisco,
USA) in combination with the Roche High Fidelity Fast
Start Kit (Roche, Basel, Switzerland).
A 10 μl PCR master mix was prepared for each sample
and contained 1 μl 10x buffer mix without MgCl2 (Roche
High Fidelity Fast Start Kit), 1.8 μl 25 mM MgCl2, 0.5 μl
DMSO, 0.5 μl 20xAA Loading Reagent (Fluidigm Corpor-
ation, South San Francisco, USA), 0.2 μl 10 mM dNTPs
each (Roche High Fidelity Fast Start Kit), 0.1 μl Fast Start
High Fidelity Taq Polymerase (5 U/μl) (Roche High
Fidelity Fast Start Kit) and 1.9 μl PCR grade water. 6 μl
PCR master mix, 2 μl DNA and 2 μl barcode primers
(2 μM equimolar mix of index 1 and index 2, Additional
file 1) were mixed in a 384 well plate using a Tecan EVO
robotic station (Tecan, Männedorf, Switzerland). 4.5 μl
of the mix were transferred to the sample inlets of a
primed 48.48 Fluidigm Access Array by the Tecan
EVO. 4 μl target specific primers (1 μM in 1×AA loading
reagent) were transferred to the primer inlets. Target
specific and index primer were obtained from metabion
(metabion international AG, Martinsread, Germany).
After loading, the chip was placed in an IFC Controller
AX (Fluidigm Corporation, South San Fransisco, USA) for
loading the PCR reagents before the PCR was performed
on a FC1 cycler. Thermal profile was 50°C for 2 min, 70°C
for 20 min, 95°C for 10 min, followed by 32 cycles at 95°C
for 25 s, 60°C for 30 s and 72°C for 90 s, and a finishing
step at 72°C for 5 min. The PCR products were har-
vested from the PCR chambers by an IFC Controller AX
(Fluidigm Corporation, South San Francisco, USA).
Dual indexing primers
Please refer to the supplementary information for the
concept, indices and sample sheet information.
Amplicon pooling, purification and quantification
The 48 samples of an Access Array chips were pooled. 8
pools were purified in parallel using AMPure XP (Beckman
Coulter, Brea, USA) with a ratio of 0.7:1 beads to DNA. Puri-
fied amplicon pools were diluted 1:4000 for quantification byqPCR using an ECO Real-Time PCR cycler (Illumina, San
Diego, USA) and the Library Quant Illumina Kit (KAPA
Biosystems, Boston, USA) with standards in a range from
0.2 fM to 20 pM. Pooling, purification and dilution for
quantification were performed on a Biomek 3000 worksta-
tion (Beckman Coulter, Brea, USA).
Library preparation and MiSeq run
8 purified and quantified amplicon pools were mixed in
equimolar amounts. The library was prepared as recom-
mended by Illumina (MiSeq Reagent Kit v2 – Reagent
Preparation Guide) and was loaded at 7.5 pM on one
MiSeq flowcell with 10% phiX spiked in. Paired end se-
quencing was performed with 251 cycles.
Prior to the update of Real-Time Analysis Software
(Illumina, San Diego, USA) to version 2.2.0.2, hardcoded
matrix and phasing values were used for sequencing
runs.
Classification of reads for primer optimization
Primer sets to be tested were combined with samples of
known HLA types on the Fluidigm chip and processed
as described above. To assess the quality of the primer
sets, the resulting MiSeq reads were classified in two
ways: 1) Finding the most similar HLA allele(s) amongst
all known HLA alleles by simple 10mer comparison. Up
to 10 mismatches were allowed when considering the
read as “matched” to a reference allele. Reads with more
than 10 mismatches were classified as “not matched”. 2)
Base by base comparison of reads with all known HLA
alleles. The classification was based on the Q values of the
mismatches. If the sum of the Q values of non-matching
bases (Qsum) was >80, the read was regarded as “not
matching”. If the read matched considerably worse (Qsum
difference >50) to the reference allele than to an allele as
determined by approach 1, the read was regarded as
“other HLA allele”. If the read matched to both alleles on
the basis of the above criteria, the read was assigned to
the allele with the lower Qsum. Reads fulfilling the match-
ing criteria were tested to determine whether existing mis-
matches could be explained by PCR crossover, i.e. artificial
recombinations of the two alleles during PCR. Those
reads were classified as “Allele n with crossover” if at least
two bases with good Q value (>25) matched to the alter-
nate allele. Depending on PCR conditions and primer set,
a considerable portion of the reads could be identified as
“crossover” products. Reads fulfilling the matching criteria
were tested to determine whether existing mismatches
could be explained by PCR crossover. Those reads were
classified as “Allele n with crossover” if at least two bases
with good Q value (>25) matched to the alternate allele.
“Not matched” reads were tested base by base against al-
lele1 or allele2. If matching criteria were met, those reads
were classified as “crossover”. In order to assess allele
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on the classification for each primer set.
neXtype
neXtype is designed for HLA typing from raw data
provided by the Illumina MiSeq system. The methods
implemented within neXtype take advantage of the
large number of reads per sequence and the associated
quality values (Q values). The software is specifically
adapted to a paired-end amplicon sequencing approach.
NeXtype is implemented as an Oracle PL/SQL appli-
cation and scalable to any number of CPU cores and
Oracle instances.
In a pre-typing run, neXtype assembles the input data
that is independent of each specific run, such as HLA
reference sequences from the IMGT/HLA database and
primer information. The typing run itself is organized
into several consecutive steps: primer recognition, allele
matching, result classification, exon combination, result
rating, and user interaction.
Primer recognition
Primer recognition is carried out for each MiSeq read to
assign HLA locus and exon. Primer recognition involves
three levels:
Firstly, a string comparison between primer library
and read is carried out.
If no match can be found then the read is compared
to known artifacts of the primer set collected in a look-
up table.
If no match is found either, then on the third level the
read is evaluated base-wise under consideration of Q
values. For ease of calculation, we convert the Q values
into numeric probabilities Qp = 1-(1/(10
(Q/10)). The pri-
mer sequence information is organized in a tree struc-
ture. At the beginning, all primers are considered to be
equally probable matches for the given read and hence
assigned a probability of pprimer = 1. Subsequently, each
branch in the primer tree is compared with the base of
the read sequence in a recursive manner. If the base at
position n in the read matches a certain branch in the
primer tree then that branch is followed and pprimer is
multiplied by the respective Qp. If the branch does
not match the primer base then that branch is
followed, too, but pprimer is multiplied by (1-Qp). All
branches are followed as long as pprimer does not drop
below a predefined limit pmin. When the read has
been compared to each primer the process is stopped
and the primer with the highest probability pprimer is
retained as match if pprimer is sufficiently higher than
the second best value (Figure 7). The sequence of the
read that most closely matched a primer is stored in
the primer artifacts look-up table for more rapid compari-
son of future reads.Allele matching
Allele matching is carried out on exon level. Since vari-
ous HLA alleles are identical over specific exons, we
group such alleles into Exon Allele Groups (EAG).
Matching of EAG is achieved by pre-assembling IMGT/
HLA DNA database information in a tree structure
under consideration of possible insertions and deletions
in the introns. As MiSeq provides two reads for each
typed exon, one in a forward and one in a reverse direc-
tion, and the read length is currently set to 251 bases, a
value smaller than the typical exon length, the EAG are
further grouped into partial EAG (PEAG) which include
all alleles that have the same sequence in a given part of
the exon for forward and reverse direction separately as
determined by the read length. Each read is matched
against all possible PEAG in a tree-structured manner
just as in the third level of primer recognition. For each
read, possible EAG are identified from the matched
PEAG and associated with the respective probabilities
pEAG (Figure 8). Each EAG encompasses a total number
of reads that are in principle similar enough to the EAG
(“match”) which has the highest matching probability
pEAG – given the respective Qp values – to the EAG
(“best match”) or, moreover, which is associated with
only this specific EAG as “best match” (“single best
match”). Only EAGs that score at least 5 “best match”
reads are subsequently considered.
Result classification
In typical cases, for each locus and exon more than two
EAG are identified. NeXtype ranks these EAGs by score,
i.e. number of “best match” reads in descending order.
The possible classification of an EAG is as follows: result,
potential new allele, noise, cross-over, and co-amplification.
A base-by-base comparison of all “best match” reads to the
EAG allows identification of potentially new alleles by iden-
tifying systematically occurring SNPs and evaluating the
number of reads with this alteration. Likewise, the consen-
sus sequence is determined based on the majority of base
calls at each position. Using a binomial distribution, EAGs
are checked pairwise to determine whether their occur-
rence can be explained as noise of higher scoring EAGs,
given the number of reads and their Q values. EAGs are
classified as “cross-over” if their consensus sequence can
be obtained by combination of any two higher scoring
EAGs. The consensus sequence is matched against
the HLA system to identify off target PCR products
(e.g. HLA-H, -DRB3, …). Those are marked as “co-
amplificate”. EAGs not scoring at least 1/50 of the best
scoring EAG are discarded. All EAGs not classified in the
above categories are considered “results” by neXtype. If
more than two EAGs are classified as “result”, neXtype in-
dicates a warning or error depending on the relative num-
ber of “best matches” of the EAG.
Figure 7 Schematic representation of primer recognition level three. In this example, primer 5 would have been assigned to the
tested read.
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The final HLA assignments are obtained by combining
the “results” from each exon. Only alleles that can be
found in the two EAGs classified as “result” with the
highest number of “best matches” in each exon become
part of the final typing result. In addition to EAGs classi-
fied as “result”, EAGs classified as “co-amplificate” are
considered if they are needed to generate a valid result.
Exons with less than 20 reads in sum over all “result”
EAGs are ignored. The collected alleles are coded into
NMDP multi-allele or G codes [20,21]. In cases where
results of exon 2 and exon 3 lead to more than one pos-
sible combination of exons (exon-shuffling), not all am-
biguities can be resolved, thus resulting in intermediate
resolution typing results.
Result rating
To rate the quality of HLA assignments, neXtype uses
several parameters, including the percentage of successfulFigure 8 Sketch showing generation of EAGs and PEAGs in forward a
of one HLA allele on a specific locus and exon. The chart shows how the Eprimer matches, the share of reads with a successful asso-
ciation to an EAG, and the percentage of reads in an exon
which contribute to the final result in this specific exon.
Each parameter has two predefined thresholds allowing
classification of the HLA assignment’s quality. If a param-
eter exceeds the upper threshold, it scores 1, whereas if it
falls below the lower threshold, it scores 0 and between
the two thresholds the score is linearly interpolated be-
tween 0 and 1. The final rating is the product over all par-
ameter scores. Furthermore, exons are checked for
possible suppressed alleles using different thresholds de-
pending on whether a homozygous or heterozygous result
is retained.
User interaction
All classified EAGs are displayed for each exon. The user
is permitted to include or exclude EAGs from each
exon based on his assessment and to recombine the
exons for a final typing result. Any user interaction triggersnd reverse read direction. Each row represents the exon sequence
AGs and PEAGs in forward and reverse direction are generated.
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mark individual EAGs as known artifacts that should
be ignored in future runs. When the user agrees with
the HLA assignment by neXtype, a status “finished” can
be set and the result is submitted electronically. HLA as-
signments achieving an overall rating of 1 are automatic-
ally submitted.
Additional file
Additional file 1: Sequence information for the dual indexing,
4-primer approach is available as part of an additional file.
Sequences include inner and outer primers, index sequences for index 1
(96 sequences) and index 2 (16 sequences) as well as a model sample
sheet.
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